DiagnoCure

The plan, which is subject to shareholder approval, comes after the company failed to find buyers for its prostate and colorectal cancer tests.

The life sciences company said the loss is mostly attributable to a decrease in royalty revenue from its PCA3 prostate cancer biomarker assets.

Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.

The firm also said that it is looking for marketing partners for its multimarker urine-based prostate cancer test, which was validated in 500 patients.

NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income.

NEW YORK (GenomeWeb) — Canadian cancer diagnostics firm DiagnoCure said this week that it has granted an exclusive license to China's Shuwen Biotech to commercialize DiagnoCure's Previstage GCC colorectal cancer staging test in China, Hong Kong, and Taiwan.

Unhappy with the sales of its urine-based molecular test for the prostate cancer biomarker PCA3, Canadian cancer diagnostics firm DiagnoCure is urging Hologic, the test's commercial conduit, to either step up commercialization efforts or relinquish rights to the test back to Diag

NEW YORK (GenomeWeb News) – Cancer diagnostics firm DiagnoCure said on Friday that revenues for the first quarter of its fiscal year 2014 decreased 12 percent year over year.

NEW YORK (GenomeWeb News) – Canadian cancer diagnostics firm DiagnoCure reported after the close of the market on Monday that revenues for its fiscal second quarter fell 85 percent year over year.

NEW YORK (GenomeWeb News) – Cancer diagnostic development company DiagnoCure reported after the close of the market Monday a 70 percent reduction in revenues in its fiscal first quarter.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.